{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T07:18:55Z","timestamp":1768807135109,"version":"3.49.0"},"posted":{"date-parts":[[2025,10,21]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":23,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>The relatively mild impact of COVID-19 in sub-Saharan Africa has raised questions about the role of pre-existing immunity in the region. One hypothesis for this unexpected observation is the presence of pre-existing cross-protective immunity, potentially induced by prior exposure to seasonal and zoonotic coronaviruses. However, the prevalence and functional relevance of such antibodies in the Senegalese population are not fully known.<\/jats:p>\n                <jats:p>To investigate this, we conducted a cross-sectional seroprevalence study using 822 plasma samples collected in Senegal before (2017\u20132019) and during (2020\u20132022) the pandemic, across regions of high (K\u00e9dougou) and low (Thi\u00e8s) malaria endemicity. Samples were screened for anti-SARS-CoV-2 spike 1 IgG using enzyme-linked immunosorbent assay (ELISA), and a subset of the pre-pandemic IgG-positive samples was further tested for neutralizing activity using a surrogate virus neutralization test (sVNT).<\/jats:p>\n                <jats:p>Pre-pandemic SARS-CoV-2 IgG positivity was 39.1% [34.6 - 43.7]. No significant differences were observed in terms of age, sex, region, or malaria status. However, only 5.1% of pre-pandemic IgG-positive samples showed neutralizing activity, with 1.3% [0.1 - 6.7] in K\u00e9dougou and 9.2% [4.5 - 17.8] in Thi\u00e8s. During the pandemic, IgG seroprevalence increased from the baseline around 40% in 2020 (37.3 % [27.7 - 48.1] in Kedougou and 50%[29.03 - 70.9%] in Thies), peaking near 99% of the study population by 2022 with 98.2% [93.8 - 99.5] in Kedougou and 98.8% [93.6 - 99.7] in Thies.<\/jats:p>\n                <jats:p>These results indicate widespread pre-pandemic cross-reactivity to SARS-CoV-2 in Senegal, likely driven by exposure to related coronaviruses. However, their poor neutralizing activity implies limited cross-protection. These findings highlight the need for further investigation into the origins, nature, and immunological significance of these cross-reactive antibody responses.<\/jats:p>","DOI":"10.1101\/2025.10.20.25337295","type":"posted-content","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:45:25Z","timestamp":1761072325000},"source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 Serosurveillance Reveals Pre-pandemic Cross-Reactivity and Pandemic Seroprevalence Trends in Senegal"],"prefix":"10.64898","author":[{"given":"Mouhamad","family":"Sy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Baudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahima M.","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariama","family":"Toure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Gaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tolla","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida S.","family":"Badiane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awa B.","family":"Deme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jules","family":"Gomis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daba","family":"Zoumarou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouhamadou","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khadim","family":"Diongue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mame Cheikh","family":"Seck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djiby","family":"Sow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngayo","family":"Sy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouhamadou A.","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marietou F.","family":"Paye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pardis C.","family":"Sabeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine J.","family":"Siddle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daouda","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025102313250477000_2025.10.20.25337295v1.1","unstructured":"World Health Organization 2023 data.who.int, WHO Coronavirus (COVID-19) dashboard > More resources [Dashboard]."},{"key":"2025102313250477000_2025.10.20.25337295v1.2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/d41586-021-03821-8","article-title":"Nkengasong. Two years of COVID-19 in Africa: lessons for the world","volume":"601","year":"2022","journal-title":"Nature"},{"key":"2025102313250477000_2025.10.20.25337295v1.3","doi-asserted-by":"crossref","unstructured":"Diarra, M. et al. First wave COVID-19 pandemic in Senegal: Epidemiological and clinical characteristics. PLoS One 17, (2022).","DOI":"10.1371\/journal.pone.0274783"},{"key":"2025102313250477000_2025.10.20.25337295v1.4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijregi.2022.02.007","article-title":"Seroprevalence of anti-SARS-CoV-2 antibodies in Senegal: a national population-based cross-sectional survey, between October and November 2020","volume":"3","year":"2022","journal-title":"IJID Regions"},{"key":"2025102313250477000_2025.10.20.25337295v1.5","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2022.43.204.38290"},{"key":"2025102313250477000_2025.10.20.25337295v1.6","unstructured":"Mbow, M. et al. Immune responses to SARS-CoV-2 in sub-Saharan Africa and western Europe: a retrospective, population-based, cross-sectional study. Lancet Microbe 6, (2025)."},{"key":"2025102313250477000_2025.10.20.25337295v1.7","doi-asserted-by":"crossref","unstructured":"Borrega, R. et al. Cross-reactive antibodies to sars-cov-2 and mers-cov in pre-covid-19 blood samples from sierra leoneans. Viruses 13, (2021).","DOI":"10.3390\/v13112325"},{"key":"2025102313250477000_2025.10.20.25337295v1.8","doi-asserted-by":"crossref","unstructured":"Souris, M. et al. Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations. Viruses 14, (2022).","DOI":"10.3390\/v14102259"},{"key":"2025102313250477000_2025.10.20.25337295v1.9","doi-asserted-by":"crossref","unstructured":"Herrera, B. B. et al. Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal. Front Public Health 13, (2025).","DOI":"10.3389\/fpubh.2025.1522733"},{"key":"2025102313250477000_2025.10.20.25337295v1.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-00468-6"},{"key":"2025102313250477000_2025.10.20.25337295v1.11","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.3201\/eid2811.221041","article-title":"Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand","volume":"28","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2025102313250477000_2025.10.20.25337295v1.12","unstructured":"Lapidus, S. et al. Plasmodium infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-CoV-2 Spike protein. Sci Rep 12, (2022)."},{"key":"2025102313250477000_2025.10.20.25337295v1.13","doi-asserted-by":"crossref","unstructured":"Pedersen, J. et al. Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic. Sci Rep 12, (2022).","DOI":"10.1038\/s41598-022-17241-9"},{"key":"2025102313250477000_2025.10.20.25337295v1.14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3201\/eid2802.211725","article-title":"SARS-CoV-2 Cross-Reactivity in Prepandemic Serum from Rural Malaria-Infected Persons, Cambodia","volume":"28","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2025102313250477000_2025.10.20.25337295v1.15","doi-asserted-by":"crossref","unstructured":"Namuniina, A. et al. Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+ T-cell responses: A pilot study. PLOS Global Public Health 3, (2023).","DOI":"10.1101\/2023.01.16.23284626"},{"key":"2025102313250477000_2025.10.20.25337295v1.16","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/S2666-5247(22)00295-6","article-title":"Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-sectional study","volume":"4","year":"2023","journal-title":"Lancet Microbe"},{"key":"2025102313250477000_2025.10.20.25337295v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.11.008"},{"key":"2025102313250477000_2025.10.20.25337295v1.18","doi-asserted-by":"crossref","unstructured":"Ayoub, H. H. et al. Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Glob Epidemiol 3, (2021).","DOI":"10.1016\/j.gloepi.2021.100068"},{"key":"2025102313250477000_2025.10.20.25337295v1.19","doi-asserted-by":"crossref","unstructured":"Klompus, S. et al. Cross-Reactive Antibodies against Human Coronaviruses and the Animal Coronavirome Suggest Diagnostics for Future Zoonotic Spillovers. Sci. Immunol vol. 6 (2021).","DOI":"10.1126\/sciimmunol.abe9950"},{"key":"2025102313250477000_2025.10.20.25337295v1.20","unstructured":"PREDICT Consortium. Advancing Global Health Security at the Frontiers of Disease Emergence. https:\/\/www.publications.predict.global (2020)."},{"key":"2025102313250477000_2025.10.20.25337295v1.21","doi-asserted-by":"crossref","unstructured":"Thiam, F. et al. Serological survey in a university community after the fourth wave of COVID-19 in Senegal. PLoS One 19, (2024).","DOI":"10.1101\/2024.01.28.24301904"},{"key":"2025102313250477000_2025.10.20.25337295v1.22","doi-asserted-by":"crossref","unstructured":"Trape, J. F. et al. One hundred malaria attacks since birth. A longitudinal study of African children and young adults exposed to high malaria transmission. EClinicalMedicine 67, (2024).","DOI":"10.1016\/j.eclinm.2023.102379"},{"key":"2025102313250477000_2025.10.20.25337295v1.23","doi-asserted-by":"crossref","unstructured":"Tairou, F. et al. Malaria prevalence and use of control measures in an area with persistent transmission in Senegal. PLoS One 19, (2024).","DOI":"10.1371\/journal.pone.0303794"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.20.25337295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:49:10Z","timestamp":1768510150000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.10.20.25337295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":23,"URL":"https:\/\/doi.org\/10.1101\/2025.10.20.25337295","relation":{},"subject":[],"published":{"date-parts":[[2025,10,21]]},"subtype":"preprint"}}